Amenalief 200 mg tablets (herpes)
What are Amenalief tablets?
Amenalief tablets are effective for the treatment of the herpes virus in a short period of time. Their active principle, amenamevir, inhibits the multiplication of the varicella-zoster virus by inhibiting the activity of the helicase-primase complex. This, in turn, is necessary for viral DNA replication.
Amenalief tablets' package is designed for a course of one week. This is usually enough to suppress the development of the herpes virus as a primary course.
Active principle: amenamevir
Amount: 14 tablets
Maker: Maruho Co., Ltd., Osaka, Japan
Indications: herpes zoster treatment
How to take
Adults should take 2 tablets (400 mg of amenamevir) at a time, once a day, after a meal.
Contraindications:
- This medicine is not indicated for children under 6 years old, for children of 6-15 years old the treatment may be performed only under strict monitoring of pediatrician in charge, and the dosage and regimen are to be decided by the pediatrician according to age, weight and symptoms.
- Amenamevir is strictly contraindicated for use in the first trimester of pregnancy. Do not use it in the second and third trimesters of pregnancy, except in cases of extreme necessity, in those cases the possible risks and benefits should be discussed with the doctor in charge. Do not use for the breastfeeding mothers.
- Do not use for patients with recent myocardial infarction, myocardial conduction blockages, arrhythmias, mania, severe hepatic insufficiency, closed-angle glaucoma, urinary retention, hypersensitivity to clomipramine and other tricyclic antidepressants of the dibenzazepine derivatives group.
Important information
Avoid taking grapefruit juice and any food or supplement containing St. John's wort while taking this medicine as those may affect medicinal effects.
If an allergic reaction occurs, patients needs to stop taking the medicine and consult with their doctor. If patient is taking any other medication or treatment, they should consult with their doctor in advance.